Live
- Yashoda Medicity organizes “Crown of Courage” ceremony to honor Cancer Survivors
- AAP appoints two-time legislator Arora as Punjab chief
- BJP won’t succeed in toppling Congress govt: K’taka Home Minister
- Turkey neutralises five Kurdish militants in Syria
- BJP questions Kejriwal on 21,000 deaths in Delhi due to contaminated water
- CM Revanth Reddy Inspects Progress of Telangana Mother Statue Installation
- ‘It’s Congress habit to spread lies’, says Vinod Tawde after sending legal notice to Kharge, Rahul
- Hungarian PM invites Netanyahu for visit, calls ICC warrants 'brazen and cynical'
- Lt Gen Suchindra Kumar reviews indigenously developed ‘Asmi’ machine pistols
- In politics, there are very few 'untouchables', says Ramesh Chennithala ahead of Maha poll results
Cipla launches 'ELIFast' for COVID-19 antibody detection in India
Cipla launches 'ELIFast' for COVID-19 antibody detection in India
Drug firm Cipla Limited on Wednesday announced the launch of antibody detection kits for COVID-19 in India under the brand name ‘ELIFast’ (IgG ELISA test).
Drug firm Cipla Limited on Wednesday announced the launch of antibody detection kits for COVID-19 in India under the brand name 'ELIFast' (IgG ELISA test). The kit was launched in partnership with KARWA Ltd. under the technology transfer from the Indian Council of Medical Research (ICMR).
The product will be marketed under the brand name 'ELIFast'.
Cipla in its release has said, ": Cipla has announced the commercialisation of antibody detection kits for
COVID-19 in India. In partnership with KARWA Ltd. under the technology transfer from the Indian Council of Medical Research (ICMR)."
As part of this collaborative effort, Cipla will be responsible for the marketing and distribution of the SARS CoV-2-IgG antibody detection ELISA that will be manufactured by KARWA Ltd. ICMR has provided the requisite technical know-how and process for developing the test kits to the approved manufacturers.
The product will be marketed under the brand name 'ELIFast'. Cipla's expansive distribution network will help in ensuring the seamless supply of kits across the country. Supply will be undertaken through the channels approved by ICMR, to ensure equitable access.
IgG Antibody tests identify the immune status of the individuals to the COVID-19 infection. ICMR has recommended these tests for conducting sero-surveillance. Serosurveillance may help in determining the burden of COVID-19 at the community level and monitor the trends in the transmission of SARS-CoV-2 infection.
ELIfast has been validated and approved by ICMR and the National Institute of Virology (NIV), Pune. It is found to have specificity and sensitivity of 99.33% and 92% respectively. The kit is user friendly with a simple protocol with ready-to-use reagents and is compatible with common ELISA equipment.
